1. Home
  2. Browse Decisions
  3. F.3d
  4. 933 F.3d
  5. 933 F.3d 1367 (2019)
 

SANOFI-AVENTIS U.S. v. DR. REDDY'S LABORATORIES

2018-1804, 2018-1808, 2018-1809.

933 F.3d 1367 (2019)

SANOFI-AVENTIS U.S., LLC, Sanofi Mature IP, Sanofi, Plaintiffs-Appellants v. DR. REDDY's LABORATORIES, INC., Dr. Reddy's Laboratories, Ltd., Sandoz, Inc., Defendants-Appellees Fresenius Kabi USA, LLC, Accord Healthcare, Inc., Apotex Corp., Apotex Inc., Actavis LLC, Actavis Elizabeth LLC, Mylan Laboratories Limited, Defendants-Cross-Appellants.

United States Court of Appeals, Federal Circuit.

Decided: August 14, 2019.

Attorney(s) appearing for the Case

William E. Solander , Venable LLP, New York, NY, argued for plaintiffs-appellants. Also represented by Katherine Adams , Dominick A. Conde , Whitney Lynn Meier , Daniel John Minion .

Emily L. Rapalino , Goodwin Procter LLP, Boston, MA, argued for all defendants-cross-appellants. Defendants-cross-appellants Fresenius Kabi USA, LLC, Actavis LLC, Actavis Elizabeth LLC also represented by Daryl L. Wiesen , Eric Romeo ; Aviv Zalcenstein , New York, NY.

Andrew M. Alul , Taft, Stettinius & Hollister, LLP, Chicago, IL, argued for all defendants-cross-appellants. Defendants-cross-appellants Apotex Corp., Apotex Inc. also represented by Roshan Shrestha .

Frank Rodriguez , Windels Marx Lane & Mittendorf LLP, Madison, NJ, for defendants-appellees Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. Also represented by James Barabas .

Laura A. Lydigsen , Brinks Gilson & Lione, Chicago, IL, for defendant-appellee Sandoz, Inc. Also represented by Mark Herbert Remus , Joshua James .

Imron T. Aly , Schiff Hardin, Chicago, IL, for defendant-cross-appellant Accord Healthcare, Inc. Also represented by Helen H. Ji .

Matthew R. Reed , Wilson, Sonsini, Goodrich & Rosati, PC, Palo Alto, CA, for defendant-cross-appellant Mylan Laboratories Limited. Also represented by Wendy L. Devine , Kristina M. Hanson , San Francisco, CA.

Before Lourie, Moore, and Taranto, Circuit Judges.

Plaintiffs-Appellants (collectively, "Sanofi") appeal from the judgment of the U.S. District Court for the District of New Jersey holding, after a bench trial, claims 7, 11, 14-16, and 26 of U.S. Patent 8,927,592 (the "'592 patent") invalid as obvious. Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC, No. 14-7869...

Let's get started

Leagle.com

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.

  • Updated daily.
  • Uncompromising quality.
  • Complete, Accurate, Current.

Listed below are the cases that are cited in this Featured Case. Click the citation to see the full text of the cited case. Citations are also linked in the body of the Featured Case.

Cited Cases

  • No Cases Found

Listed below are those cases in which this Featured Case is cited. Click on the case name to see the full text of the citing case.

Citing Cases